Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Signal Transduction and Targeted Therapy · 26.04.2024 · 9 (1)
DOI: 10.1038/s41392-024-01809-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Signal Transduction and Targeted Therapy, online erschienen am 26.04.2024. Verfasst von Jonas Cerneckis und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Cellular Reprogramming, COVID-19. Die Arbeit wurde bisher 488-mal zitiert (Crossref) und nennt 498 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
The induced pluripotent stem cell (iPSC) technology has transformed in vitro research and holds great promise to advance regenerative medicine. iPSCs have the capacity for an almost unlimited expansion, are amenable to genetic engineering, and can be differentiated into most somatic cell types. iPSCs have been widely applied to model human development and diseases, perform drug screening, and develop cell therapies. In this review, we outline key developments in the iPSC field and highlight the immense versatility of the iPSC technology for in vitro modeling and therapeutic applications. We begin by discussing the pivotal discoveries that revealed the potential of a somatic cell nucleus for reprogramming and led to successful generation of iPSCs. We consider the molecular mechanisms and dynamics of somatic cell reprogramming as well as the numerous methods available to induce pluripotency. Subsequently, we discuss various iPSC-based cellular models, from mono-cultures of a single cell type to complex three-dimensional organoids, and how these models can be applied to elucidate the mechanisms of human development and diseases. We use examples of neurological disorders, coronavirus disease 2019 (COVID-19), and cancer to highlight the diversity of disease-specific phenotypes that can be modeled using iPSC-derived cells. We also consider how iPSC-derived cellular models can be used in high-throughput drug screening and drug toxicity studies. Finally, we discuss the process of developing autologous and allogeneic iPSC-based cell therapies and their potential to alleviate human diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.
- Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.
- Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA. yshi@coh.org.
- Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA. yshi@coh.org.
ORCID-Profile: Yanhong Shi
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
- U.S. Department of Health & Human Services | NIH | National Institute on Aging
Zitieren
APA
Cerneckis, J., Cai, H., & Shi, Y. (2024). Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduction and Targeted Therapy, 9(1). https://doi.org/10.1038/s41392-024-01809-0
Vancouver
Cerneckis J, Cai H, Shi Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduction and Targeted Therapy. 2024;9(1). doi:10.1038/s41392-024-01809-0
BibTeX
@article{Cerneckis2024,
author = {Cerneckis, Jonas and Cai, Hongxia and Shi, Yanhong},
title = {Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications},
journal = {Signal Transduction and Targeted Therapy},
year = {2024},
volume = {9},
number = {1},
doi = {10.1038/s41392-024-01809-0}
}
EUVIMED